AUTISM THERAPEUTICS
Autism Therapeutics ("AT") is a biopharmaceutical company seeking to develop pharmaceutical therapies to treat the unmet medical needs of patients with Autism Spectrum Disorders, Rett Syndrome and Fragile X Syndrome.
Scientific Approach
Current research suggests autism spectrum disorders may result, in part, from issues of neuronal connectivity. For this reason, Autism Therapeutics has adopted a number of therapeutic approaches that have potential to remedy neuronal connectivity issues. At the present time Autism Therapeutics is developing a novel therapeutic (AT002) to address connectivity issues that are known to occur in Fragile X Syndrome. AT is also contracted to advance the development of another compound that addresses under-connectivity issues in a syndromic form of autism that is currently entering Phase II clinical trials. Collectively, the Company and its collaborators are passionate in the belief that these approaches may facilitate brain development and so reduce the difficulties that are experienced in Autism Spectrum Disorders.
Since autism is a complex and heterogeneous disorder, Autism Therapeutics is heavily focused on defining phenotypic subpopulations that relate to treatment response within Autism Spectrum Disorders. The Company uses this approach to allow enrichment designs in clinical studies that align appropriate therapies to particular patient groups, rather than following the traditional "one size fits all" mentality.
No comments:
Post a Comment